
What could oral GLP-1s change about who starts, switches or stays on obesity treatment?
What’s new?
Wegovy, which many people know as a weekly injection, is now also available as a daily tablet in the US. A second daily tablet, Foundayo, was approved by the US Food and Drug Administration in April 2026. Both are prescription weight loss medicines from a group called GLP-1s, which can help people feel fuller and manage their appetite.
Even two tablets can fit differently into someone’s day. Oral Wegovy is taken on an empty stomach, with a wait of at least 30 minutes before food, other drinks or other oral medicines. Foundayo can be taken with or without food. For someone who works shifts or already takes several medicines in the morning, those details could influence which option feels more manageable.
For a multi-market brief, we’d assess which groups are feasible to recruit in each country. Where tablets are already available, for example, researchers can speak to people who have switched. In markets where access is more limited, the study may be better placed to explore what patients and prescribers would consider if a tablet became available.
Research methods
If you’re scoping an obesity study, QQFS can help you define eligibility criteria, assess recruitment feasibility by market and reach the patients and healthcare professionals who can answer your brief. Discuss your fieldwork brief with QQFS.
Research methods
ObesityWeek runs 14–17 November 2026 in Washington, DC. Scheduled presentations include research on what patients and healthcare professionals value in obesity medicines, as well as early experiences with oral semaglutide among people who started treatment through telehealth. View the ObesityWeek programme.